Senores Pharmaceuticals

Buford, United States Founded: 2017 • Age: 9 yrs Listed
Pharmaceutical drugs are manufactured by Senores Pharmaceuticals.
Request Access
Report Incorrect Data
Page last updated

About Senores Pharmaceuticals

Senores Pharmaceuticals is a publicly listed company based in Buford (United States) founded in 2017 by Anar Swapnil Shah, Swapnil Jatinbhai Shah, and Pinkyben Jatinbhai Shah. Pharmaceutical drugs are manufactured by Senores Pharmaceuticals. Senores Pharmaceuticals has raised $3.66 million across 3 funding rounds from investors including Prakash Sanghvi, Jayanti Sanghvi and Jigar Sanghvi. The company has 194 employees. Senores Pharmaceuticals was last valued at $5.71 million in October 2021. Its website senorespharma.com draws about 15 thousand monthly visits. Its Indian entity Senores Pharmaceuticals Limited reported revenue of ₹680 Cr. Senores Pharmaceuticals offers products and services including Complex Generics and API and Intermediates. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Senores Pharmaceuticals was established in 2017 and is based in Buford, United States. Operations are centered on the manufacturing of pharmaceutical drugs within the healthcare sector. The company is led by co-founders Anar Swapnil Shah, Swapnil Jatinbhai Shah as managing director, and Pinkyben Jatinbhai Shah. Drug production activities are conducted to support pharmaceutical needs, with a focus on standard industry practices in the region.

  • Headquarters Buford, United States
  • Employees 194
  • Founders Anar Swapnil Shah, Swapnil Jatinbhai Shah, Pinkyben Jatinbhai Shah
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website senorespharma.com
  • Social LinkedIn
  • Legal Name Senores Pharmaceuticals Ltd.
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹5,282 Cr

    SENORES · NSE

  • Share Price
    ₹1,137.00

    -0.87% today

  • Revenue
    ₹633 Cr

    FY 2025-26 · +58.9% YoY

  • EBITDA
    ₹168 Cr

    Margin 26.6%

  • Net Profit
    ₹115 Cr

    FY 2025-26 · +97.0% YoY

  • P/E (TTM)
    38.6x

    P/B 5.1x

  • Total Equity Funding
    $3.66M (USD)

    in 3 rounds

  • Latest Funding Round
    $2.67M (USD), Angel Round

    Oct 2021

  • Employee Count
    194

Products & Services of Senores Pharmaceuticals

Senores Pharmaceuticals offers a comprehensive portfolio of products and services, including Complex Generics and API and Intermediates.

Complex Generics
Formulations

Complex generics are manufactured to fulfill a variety of medical needs, with affordability and high quality being ensured through global certifications

API and Intermediates
Active Pharmaceutical Ingredients

API and intermediates are produced for pharmaceutical applications, supporting the creation of cost-effective generics across markets

Funding Insights of Senores Pharmaceuticals

Senores Pharmaceuticals has successfully raised a total of $3.66M across 3 strategic funding rounds. The most recent funding activity was a Angel Round of $2.67 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.66M
  • Total Rounds 3
  • Last Round Angel Round — $2.67M
  • First Round $273,128

    (Nov 2019)

  • Investors Count 14

All 3 funding rounds of Senores Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2021$2.67MAngel Round$5.71MPrakash Sanghvi
Jayanti Sanghvi, Jigar Sanghvi
Nov 2020$719,594Angel Round$1.49MAshok Barot, Sangeeta Mukur Barot
Deval Rajnikant Shah, Swapnil Jatinbhai Shah
Nov 2019$273,128Angel Round$•••••Ashok Barot, Sangeeta Mukur Barot
Pankajkumar Vaghjibhai Chaudhari, Swapnil Jatinbhai Shah
Valuation history
DateValuationStage
Oct 2021$5.71M••••••••
Nov 2020$1.49M••••••••

Last known valuation $5.71M (Oct 2021). 14 investors in total: 0 institutional and 14 angel.

Investors in Senores Pharmaceuticals

Senores Pharmaceuticals has secured backing from 14 investors, including angel investors. Prominent investors backing the company include Prakash Sanghvi, Jayanti Sanghvi and Jigar Sanghvi.

All
Angel
InvestorDescriptionFounded YearDomainLocation

Prakash Sanghvi

unknown_c0d9f7bde9b443ffb

Jayanti Sanghvi

unknown_acbfbace38734b7a8

Jigar Sanghvi

unknown_eeb2c0fc462d4925b

Manoj Sanghvi

unknown_9a8dfe2b9f874e53b

Shantilal Sanghvi

unknown_8d570c2fb2df42fe9

Ravi Sanghvi

Angel investor and entrepreneur, focused on tech startups in India.
unknown_07c97435913c430fb

Shantaben Sanghvi

unknown_1844b13a1b8143ed9

Chunnilal Sanghvi

unknown_c5401824eeeb4d2ea

Ashok Barot

unknown_556c0cedcb414eefa

Sangeeta Mukur Barot

unknown_5db9f9434d1647928
Premium access

Investor details for Senores Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Senores Pharmaceuticals Limited (Senores Pharmaceuticals)

Senores Pharmaceuticals Limited is the primary company behind Senores Pharmaceuticals. The board of Senores Pharmaceuticals Limited currently have 12 directors; the longest-serving is Ashokkumar Vijaysinh Barot, appointed in 2018. 7 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ashokkumar Vijaysinh Barot
DIN 01192300
Director15 May 20188 yrs 5 moSenores Pharmaceuticals Limited
Deval Rajnikant Shah
DIN 00332722
Whole-time director01 Jan 20206 yrs 10 moSenores Pharmaceuticals Limited
Swapnil Jatinbhai Shah
DIN 05259821
Managing Director15 Oct 20215 yrsSenores Pharmaceuticals Limited
Jitendra Babulal Sanghvi
DIN 00271995
Director23 Nov 20214 yrs 11 moSenores Pharmaceuticals Limited
Arpit Deepakkumar Shah
DIN 07214641
Director10 Nov 20232 yrs 11 moSenores Pharmaceuticals Limited
Chetan Bipinchandra Shah
DIN 10381971
Whole-time director10 Nov 20232 yrs 11 moSenores Pharmaceuticals Limited
Hemanshu Nitinchandra Pandya
DIN 10383995
Director10 Nov 20232 yrs 11 moSenores Pharmaceuticals Limited
Manjula Devi Shroff
DIN 00297159
Director30 Jan 20242 yrs 9 moSenores Pharmaceuticals Limited
Kalpit Rajesh Gandhi
DIN 02843308
Director30 Jan 20242 yrs 9 moSenores Pharmaceuticals Limited
Naresh Bansilal Shah
DIN 10384306
Director30 Jan 20242 yrs 9 moSenores Pharmaceuticals Limited
Sanjay Shaileshbhai Majmudar
DIN 00091305
Director10 Feb 20242 yrs 8 moSenores Pharmaceuticals Limited
Udayan Dileep Choksi
DIN 02222020
Director08 Mar 20242 yrs 7 moSenores Pharmaceuticals Limited

People of Senores Pharmaceuticals

9 people are tracked at Senores Pharmaceuticals (5 in leadership, 4 in team); the tracked headcount is 194.

NameRoleGroup
Anar Swapnil Shah
Co-FounderLeadership
Swapnil Jatinbhai Shah
Co-Founder & MDLeadership
Pinkyben Jatinbhai Shah
Co-FounderLeadership
Swapnil Shah
Group Managing DirectorLeadership
Anar Modi
Head Of HRLeadership
Jagruti Patel
Assistant Manager - HRTeam
Amol Kolhe
Senior Manager - International Business DevelopmentTeam
Shailendera Singh Rajput
Operations ExecutiveTeam
Sourabh Singh Rajput
Senior ManagerTeam
Premium access

Complete people profiles for Senores Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Senores Pharmaceuticals

Senores Pharmaceuticals is a publicly listed company on the NSE with ticker symbol SENORES in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date30 Dec 2024
  • Listed onNSE: SENORES · BSE: 544319
  • Listed entitySenores Pharmaceuticals Ltd.
  • Exchange sectorHealth technology
  • ISININE0RB801010
  • Share price₹1,298.00 (-1.74% on the day) · 2026-10-14
  • Market capitalisation₹6,080 Cr
  • Price to earnings47.4
  • EPS (diluted, trailing year)₹27.37
  • Volume (last session)38,996

Financials of Senores Pharmaceuticals

Exchange-reported figures of Senores Pharmaceuticals Limited, the listed company behind Senores Pharmaceuticals (NSE: SENORES).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹633 Cr
+58.9% YoY
EBITDA
₹168 Cr
+87.6% YoY
Profit After Tax
₹115 Cr
+97.0% YoY
Net Worth
₹934 Cr
+18.7% YoY
Total Assets
₹1,313 Cr
+16.2% YoY
Total Debt
₹342 Cr
+8.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Income statement
Revenue63339821535.3414.17
Revenue growth+58.9%+85.7%+507.0%+149.4%-
EBITDA16889.7041.5912.681.96
EBITDA margin+26.6%+22.5%+19.4%+35.9%+13.8%
Profit before tax15970.5724.9412.441.14
Net profit11558.5631.488.430.99
Net profit margin+18.2%+14.7%+14.7%+23.9%+7.0%
EPS (₹)26.3912.7210.318.591.13
Balance sheet
Total assets1,3131,13049110851.40
Net worth93478620445.5036.59
Total debt34231525862.6014.75
Cash & bank16038613.060.103.22
Net working capital52262612030.7319.29
Cash flow
Cash from operations62.05(45.92)(25.70)(1.08)(10.45)
Cash from investing(121)(429)(53.73)(48.29)(24.44)
Cash from financing(1.33)57386.9846.2536.46
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue192180175171162138114103
Revenue growth (YoY)+18.9%+30.6%+53.4%+65.9%+60.8%+71.7%--
Other income8.942.8117.677.395.413.3611.775.16
EBITDA57.6653.7647.4950.4049.5134.1619.4425.69
EBITDA margin+30.0%+29.8%+27.1%+29.5%+32.3%+26.2%+17.0%+24.9%
Depreciation10.259.949.307.868.095.995.234.20
Interest8.777.178.465.336.195.045.306.16
Profit before tax47.5839.4647.4044.6040.6426.4920.6820.49
Tax10.989.0110.7311.0210.525.312.714.06
Net profit36.6030.4536.6733.5830.1221.1817.9716.43
EPS (₹)8.826.607.967.296.544.603.815.04
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue10638.5434.0112.3813.547.91
Revenue growth+175.3%+13.3%+174.7%-8.6%+71.2%-
EBITDA(18.68)(7.28)(0.06)(1.78)1.161.01
EBITDA margin-17.6%-18.9%-0.2%-14.4%+8.6%+12.8%
Profit before tax27.465.112.031.940.830.39
Net profit20.253.690.811.200.680.83
Net profit margin+19.1%+9.6%+2.4%+9.7%+5.0%+10.5%
EPS (₹)4.400.800.271.220.782.20
Balance sheet
Total assets84081226910148.5013.17
Net worth75070816838.9333.699.47
Total debt85.3810310160.6614.753.71
Cash & bank14636010.450.091.411.64
Net working capital20839023.5617.387.316.41
Cash flow
Cash from operations(26.88)(20.40)(19.26)(47.78)(24.06)(2.87)
Cash from investing(19.46)(436)(57.07)1.07(10.05)(4.37)
Cash from financing(2.64)53386.6845.3333.888.50
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue35.6526.9936.8125.1528.0116.1311.869.59
Revenue growth (YoY)+27.3%+67.3%+210.4%+162.3%+190.9%+115.6%--
Other income14.769.5522.1913.3818.6812.089.257.19
Total expenses34.5929.3240.2929.6933.8120.9814.6012.01
EBITDA1.06(2.33)(3.48)(4.54)(5.80)(4.85)(2.74)(2.42)
EBITDA margin+3.0%-8.6%-9.5%-18.1%-20.7%-30.1%-23.1%-25.2%
Depreciation3.933.614.133.583.651.881.270.75
Interest2.222.221.891.751.581.762.352.70
Profit before tax9.671.3912.693.517.653.592.891.32
Tax1.950.364.210.861.220.890.880.25

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue192180175171162138114103
Revenue growth (YoY)+18.9%+30.6%+53.4%+65.9%+60.8%+71.7%--
Other income8.942.8117.677.395.413.3611.775.16
EBITDA57.6653.7647.4950.4049.5134.1619.4425.69
EBITDA margin+30.0%+29.8%+27.1%+29.5%+32.3%+26.2%+17.0%+24.9%
Depreciation10.259.949.307.868.095.995.234.20
Interest8.777.178.465.336.195.045.306.16
Profit before tax47.5839.4647.4044.6040.6426.4920.6820.49
Tax10.989.0110.7311.0210.525.312.714.06
Net profit36.6030.4536.6733.5830.1221.1817.9716.43
EPS (₹)8.826.607.967.296.544.603.815.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Revenue63339821535.3414.17
Revenue growth+58.9%+85.7%+507.0%+149.4%-
Other income47.0619.262.823.680.46
Total expenses46430917322.6612.21
Employee cost0.0060.3735.464.792.86
EBITDA16889.7041.5912.681.96
EBITDA margin+26.6%+22.5%+19.4%+35.9%+13.8%
Depreciation31.2516.8410.021.780.71
Interest25.0321.559.452.140.57
Profit before tax15970.5724.9412.441.14
Tax37.5812.23(7.77)4.010.15
Net profit11558.5631.488.430.99
Net profit margin+18.2%+14.7%+14.7%+23.9%+7.0%
EPS (₹)26.3912.7210.318.591.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Equity & liabilities
Share capital46.0546.0530.519.828.74
Reserves & surplus88774017435.6827.85
Shareholders' funds (net worth)93478620445.5036.59
Minority interest30.9426.0627.440.000.00
Secured loans22718676.173.161.99
Unsecured loans11512918159.4412.76
Total debt34231525862.6014.75
Total liabilities1,3131,13049110851.40
Assets
Gross block58533124830.308.17
Net block52330123527.246.89
Capital work in progress24917297.0934.468.06
Investments4.290.010.0116.4515.41
Inventories89.2956.6337.373.122.98
Sundry debtors32512411222.1119.63
Cash & bank balances16038613.060.103.22
Loans & advances23915688.4726.011.22
Total current assets81272225151.3427.05
Total current liabilities29096.6013120.617.76
Net working capital52262612030.7319.29
Total assets1,3131,13049110851.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Opening cash1057.650.103.221.64
Net cash from operating activities62.05(45.92)(25.70)(1.08)(10.45)
Net cash from investing activities(121)(429)(53.73)(48.29)(24.44)
Net cash from financing activities(1.33)57386.9846.2536.46
Net change in cash(59.83)97.737.55(3.12)1.58
Closing cash16038613.060.103.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Growth
Sales growth+58.9%+85.7%+507.0%+149.4%-
EBITDA growth+87.7%+115.7%+228.0%+546.9%-
PBT growth+125.5%+183.0%+100.5%+991.2%+9997.0%
Net income growth+97.0%+86.0%+273.4%+751.5%-
Revenue CAGR (3Y)+161.6%+204.0%---
EBITDA CAGR (3Y)+136.8%+257.7%---
Profitability & leverage
Net income margin+19.2%+14.7%+15.3%+23.9%+7.0%
Return on capital employed-+11.8%+12.0%+18.2%+3.3%
Return on net worth-+11.8%+26.2%+20.5%+2.7%
Debt / equity-0.581.280.940.40
Long-term debt / equity-0.320.600.120.07
Interest cover18.2629.5829.9319.6345.60
Efficiency & per share
Fixed asset turnover-1.381.541.841.73
Inventory turnover-8.4710.6011.594.76
Debtors turnover-3.383.201.690.72
EPS (₹)26.3912.7210.318.591.13
Dividend per share (₹)0.000.000.000.000.00
Book value per share (₹)0.00170.7266.9546.3641.86
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue35.6526.9936.8125.1528.0116.1311.869.59
Revenue growth (YoY)+27.3%+67.3%+210.4%+162.3%+190.9%+115.6%--
Other income14.769.5522.1913.3818.6812.089.257.19
Total expenses34.5929.3240.2929.6933.8120.9814.6012.01
EBITDA1.06(2.33)(3.48)(4.54)(5.80)(4.85)(2.74)(2.42)
EBITDA margin+3.0%-8.6%-9.5%-18.1%-20.7%-30.1%-23.1%-25.2%
Depreciation3.933.614.133.583.651.881.270.75
Interest2.222.221.891.751.581.762.352.70
Profit before tax9.671.3912.693.517.653.592.891.32
Tax1.950.364.210.861.220.890.880.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue10638.5434.0112.3813.547.91
Revenue growth+175.3%+13.3%+174.7%-8.6%+71.2%-
Other income66.3521.996.846.790.940.15
Total expenses12545.8234.0714.1612.386.90
Employee cost0.0018.259.355.022.861.63
EBITDA(18.68)(7.28)(0.06)(1.78)1.161.01
EBITDA margin-17.6%-18.9%-0.2%-14.4%+8.6%+12.8%
Depreciation13.233.082.040.930.710.57
Interest6.986.522.712.140.560.20
Profit before tax27.465.112.031.940.830.39
Tax7.211.421.220.740.15(0.44)
Net profit20.253.690.811.200.680.83
Net profit margin+19.1%+9.6%+2.4%+9.7%+5.0%+10.5%
EPS (₹)4.400.800.271.220.782.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital46.0546.0530.519.828.743.80
Reserves & surplus70466213829.1124.955.67
Shareholders' funds (net worth)75070816838.9333.699.47
Secured loans37.4554.3814.913.011.990.49
Unsecured loans47.9348.3685.7857.6512.763.22
Total debt85.3810310160.6614.753.71
Total liabilities84081226910148.5013.17
Assets
Gross block11659.6528.348.292.872.26
Net block97.9254.5924.097.771.591.69
Capital work in progress12.3034.0118.4711.333.172.71
Investments15410481.588.2311.691.45
Inventories9.758.664.523.122.980.34
Sundry debtors76.4625.6922.0115.738.370.23
Cash & bank balances14636010.450.091.411.64
Loans & advances23.4218.012.988.741.225.98
Total current assets25641239.9627.6813.988.19
Total current liabilities47.9921.8716.4010.306.671.78
Net working capital20839023.5617.387.316.41
Total assets84081226910148.5013.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash81.205.230.091.411.640.39
Net cash from operating activities(26.88)(20.40)(19.26)(47.78)(24.06)(2.87)
Net cash from investing activities(19.46)(436)(57.07)1.07(10.05)(4.37)
Net cash from financing activities(2.64)53386.6845.3333.888.50
Net change in cash(48.98)75.9710.35(1.38)(0.23)1.25
Closing cash14636010.450.091.411.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+175.3%+13.3%+174.7%-8.6%+71.2%-
EBITDA growth-156.6%-+96.6%-253.5%+14.9%-
PBT growth+437.4%+151.7%+4.6%+133.7%+112.8%+9997.0%
Net income growth+448.8%+355.6%-32.5%+76.5%-18.1%-
Revenue CAGR (3Y)+104.6%+41.7%+62.6%---
EBITDA CAGR (3Y)+118.9%-----
Profitability & leverage
Net income margin+19.1%+9.6%+2.4%+9.7%+5.0%+10.5%
Return on capital employed-+2.2%+2.6%+5.4%+4.5%+4.6%
Return on net worth-+0.8%+0.8%+3.3%+3.2%+8.9%
Debt / equity-0.230.781.040.430.39
Long-term debt / equity-0.130.130.040.130.34
Interest cover-21.87-62.93-129.05-78.97124.4445.45
Efficiency & per share
Fixed asset turnover-0.851.862.225.283.50
Inventory turnover-5.858.904.068.1623.26
Debtors turnover-1.621.801.033.1534.39
EPS (₹)4.400.800.271.220.782.20
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)0.00153.7455.1039.6638.5424.91

Timeline of Senores Pharmaceuticals

5 dated milestones of Senores Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Senores Pharmaceuticals is founded.
  2. Funding First funding round of $273K.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Angel Round, of $2.7M.
  5. IPO Lists on the stock exchange (IPO).

Web traffic of Senores Pharmaceuticals

The website of Senores Pharmaceuticals (senorespharma.com) receives about 14.7K visits a month.

  • Monthly visits
    14.7K

    ▲ 179.7% vs previous month

Similar websites

Websites whose visitors overlap most with Senores Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
fullertreacymoney.com
fullertreacymoney.com
100%
#4,846,864–
EquityBulls
equitybulls.com
94%
#900,989View details
equitypandit.com
equitypandit.com
76%
#152,942–
money.rediff.com
money.rediff.com
76%
#13,922–
Capital Market
capitalmarket.com
76%
81.2K#358,709View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 9 similar websites and full traffic analytics for Senores Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Senores Pharmaceuticals (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Amneal
Manufacturer of generics formulations
2002Bridgewater, New Jersey, United StatesUSD 3.02 B8,300
Coherus Biosciences
Biosimilar therapeutics are developed for oncology and autoimmune diseases.
2010Redwood City, California, United StatesUSD 143.62 MUSD 42.17 M228
Bausch & Lomb
Ophthalmic pharmaceuticals and instruments are developed for eye care.
1853Bridgewater, New Jersey, United StatesUSD 5.1 B13,500
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Senores Pharmaceuticals

Senores Pharmaceuticals: Expects 30-40% Revenue Boost And 50-60% Growth In Net Profit For FY27.
Exchange Update • 3 days ago
SENORES: Q2 CONS NET PROFIT 390M RUPEES VS 330M (YOY)
Exchange Update • 7 days ago
SENORES: Q2 REVENUE 1.9B RUPEES VS 1.6B (YOY)
Exchange Update • 7 days ago
Senores: Company Projects 30-40% Revenue Growth And 50-60% PAT Growth For INFY27.
Exchange Update • 7 days ago
SENORES: Q2 EBITDA 576M RUPEES VS 417M (YOY); Q2 EBITDA MARGIN 29.98% VS 27.1% (YOY)
Exchange Update • 7 days ago
Senores Pharmaceuticals: Approves ₹43 Crore Expansion Plan for Subsidiaries, Featuring New Prefilled Syringe Line with Completion Anticipated by March 2027.
Exchange Update • 7 days ago
Senores Pharma: Expecting 13 ANDAs With 41 Strengths To Be Commercialized In Government Channel In H2FY27
Exchange Update • 7 days ago
Senores Pharma: Board Greenlights Reappointments Of Managing Director And Whole Time Director; Swapnil Jatinbhai Shah For Three Years Starting October 15, 2026; Chetan Bipinchandra Shah For Three Years Starting November 10, 2026, Both Awaiting Shareholder Approval.
Exchange Update • 23 days ago
Senores Pharmaceuticals Says To Incorporate Units In Mexico, Canada
Reuters • 2 months ago
Senores Pharmaceuticals Ltd June-Quarter Consol Net Profit 307.2 Million Rupees
Reuters • 3 months ago
Premium access

Complete news archive for Senores Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Senores Pharmaceuticals

Senores Pharmaceuticals was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Senores Pharmaceuticals is headquartered in Buford, United States. It is registered at Buford, Georgia, United States.

Senores Pharmaceuticals is a funded company, having raised a total of $3.66M across 3 funding rounds to date. The company's 1st funding round was a Angel Round of $273.13K, raised on Nov 2019.

Senores Pharmaceuticals has 194 employees.

The primary company behind Senores Pharmaceuticals, Senores Pharmaceuticals Limited, reported revenue of ₹680 Cr for FY 2026, up 59% year on year.

Senores Pharmaceuticals was established in 2017 and is based in Buford, United States. Operations are centered on the manufacturing of pharmaceutical drugs within the healthcare sector. The company is led by co-founders Anar Swapnil Shah, Swapnil Jatinbhai Shah as managing director, and Pinkyben Jatinbhai Shah. Drug production activities are conducted to support pharmaceutical needs, with a focus on standard industry practices in the region.

Senores Pharmaceuticals offers Complex Generics and API and Intermediates.

Yes, Senores Pharmaceuticals is publicly traded on NSE under the ticker symbol SENORES.

Senores Pharmaceuticals has 14 investors. Key investors include Prakash Sanghvi, Jayanti Sanghvi, Jigar Sanghvi, Manoj Sanghvi, and Shantilal Sanghvi.

The valuation of Senores Pharmaceuticals is $5.71M as of Oct 2021.

Senores Pharmaceuticals operates through Senores Pharmaceuticals Limited.

The legal entities of Senores Pharmaceuticals currently have 12 directors, including Ashokkumar Vijaysinh Barot, Deval Rajnikant Shah, Jitendra Babulal Sanghvi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available